$BIOLQ
BIOLASE, INC Stock $biolq

$biolq Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024034812 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$10.13M	$13.49M	$49.16M
YoY Change	-3.21%	-3.99%	1.45%
Cost Of Revenue	$6.795M	$9.966M	$32.44M
YoY Change	-4.7%	-4.68%	-0.34%
Gross Profit	$3.336M	$3.524M	$16.72M
YoY Change	-0.03%	-2.0%	5.11%
Gross Profit Margin	32.93%	26.12%	34.02%
Selling, General & Admin	$6.579M	$6.948M	$28.66M
YoY Change	-7.09%	-30.07%	-15.68%
% of Gross Profit	197.21%	197.16%	171.35%
Research & Development	$1.283M	$1.652M	$6.004M
YoY Change	-17.07%	-20.88%	-17.36%
% of Gross Profit	38.46%	46.88%	35.9%
Depreciation & Amortization	$660.0K	$668.0K	$2.798M
YoY Change	342.95%	421.88%	462.98%
% of Gross Profit	19.78%	18.96%	16.73%
Operating Expenses	$7.862M	$8.600M	$34.66M
YoY Change	-8.88%	-28.47%	-15.97%
Operating Profit	-$4.526M	-$5.076M	-$17.90M
YoY Change	-14.46%	-39.77%	-29.25%
Interest Expense	-$622.0K	-$432.0K	-$2.361M
YoY Change	7.8%	-67.95%	-14.11%
% of Operating Profit
Other Income/Expense, Net	-$1.940M	$167.0K	-$2.664M
YoY Change	248.29%		-16.41%
Pretax Income	-$6.466M	-$5.341M	-$20.60M
YoY Change	10.57%	-45.36%	-27.78%
Income Tax	$19.00K	-$15.00K	$31.00K
% Of Pretax Income
Net Earnings	-$6.485M	-$22.31M	-$20.63M
YoY Change	11.81%	126.28%	-27.95%
Net Earnings / Revenue	-64.01%	-165.4%	-41.97%
Basic Earnings Per Share	-$0.36		-$29.44
Diluted Earnings Per Share	-$0.36	-$7.31	-$29.44
COMMON SHARES
Basic Shares Outstanding	32.52M	2.297M	1.278M
Diluted Shares Outstanding	17.84M		1.278M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.393M	$6.566M	$6.566M
YoY Change	-2.13%	57.04%	57.04%
Cash & Equivalents	$6.400M	$6.600M	$6.566M
Short-Term Investments
Other Short-Term Assets	$1.652M	$555.0K	$1.381M
YoY Change	-33.89%	-52.4%	-54.77%
Inventory	$11.27M	$11.43M	$11.43M
Prepaid Expenses
Receivables	$5.700M	$5.500M	$5.483M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.01M	$24.86M	$24.86M
YoY Change	-21.77%	-14.14%	-14.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.846M	$5.525M	$7.044M
YoY Change	2.69%	29.15%	16.51%
Goodwill	$2.900M	$2.926M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$263.0K	$268.0K	$268.0K
YoY Change	2.33%	5.1%	5.1%
Total Long-Term Assets	$9.348M	$10.24M	$10.24M
YoY Change	-6.33%	10.96%	10.96%
TOTAL ASSETS
Total Short-Term Assets	$25.01M	$24.86M	$24.86M
Total Long-Term Assets	$9.348M	$10.24M	$10.24M
Total Assets	$34.35M	$35.10M	$35.10M
YoY Change	-18.1%	-8.08%	-8.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.915M	$6.065M	$6.065M
YoY Change	-34.81%	4.82%	4.82%
Accrued Expenses	$7.589M	$8.881M	$7.810M
YoY Change	-4.86%	-3.57%	1.61%
Deferred Revenue	$2.343M	$2.452M
YoY Change	12.54%	16.15%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.800M	$2.265M	$2.265M
YoY Change	100.0%	223.57%	223.57%
Total Short-Term Liabilities	$21.43M	$19.66M	$19.66M
YoY Change	12.78%	10.42%	10.42%
LONG-TERM LIABILITIES
Long-Term Debt	$11.21M	$11.78M	$11.78M
YoY Change	-10.32%	-10.0%	-10.0%
Other Long-Term Liabilities	$87.00K	$79.00K	$1.700M
YoY Change	11.54%	-78.18%	-29.14%
Total Long-Term Liabilities	$11.29M	$11.86M	$13.48M
YoY Change	-10.18%	-11.83%	-12.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.43M	$19.66M	$19.66M
Total Long-Term Liabilities	$11.29M	$11.86M	$13.48M
Total Liabilities	$34.08M	$33.15M	$33.15M
YoY Change	0.88%	-0.46%	-0.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.3M	-$316.8M
YoY Change	7.04%	6.97%
Common Stock	$322.0M	$317.1M
YoY Change	3.59%	5.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.934M	-$247.0K	$1.956M
YoY Change
Total Liabilities & Shareholders Equity	$34.35M	$35.10M	$35.10M
YoY Change	-18.1%	-8.08%	-8.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.485M	-$22.31M	-$20.63M
YoY Change	11.81%	126.28%	-27.95%
Depreciation, Depletion And Amortization	$660.0K	$668.0K	$2.798M
YoY Change	342.95%	421.88%	462.98%
Cash From Operating Activities	-$5.938M	-$2.281M	-$14.10M
YoY Change	4.95%	-59.14%	-47.39%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$181.0K	$1.311M
YoY Change	-100.0%	-61.57%	-64.82%
Acquisitions
YoY Change
Other Investing Activities	$197.0K	$182.0K	$182.0K
YoY Change
Cash From Investing Activities	$197.0K	$1.000K	-$1.129M
YoY Change	-133.56%	-100.21%	-69.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.553M
YoY Change			70.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.647M	884.0K	17.43M
YoY Change	-33.7%	-2862.5%	278.75%
NET CHANGE
Cash From Operating Activities	-5.938M	-2.281M	-14.10M
Cash From Investing Activities	197.0K	1.000K	-1.129M
Cash From Financing Activities	5.647M	884.0K	17.43M
Net Change In Cash	-173.0K	-1.396M	2.385M
YoY Change	-107.36%	-77.06%	-109.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.938M	-$2.281M	-$14.10M
Capital Expenditures	$0.00	$181.0K	$1.311M
Free Cash Flow	-$5.938M	-$2.462M	-$15.41M
YoY Change	-4.92%	-59.33%	-49.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000811240
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36385
CY2023	dei	Entity Registrant Name EntityRegistrantName	BIOLASE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0442441
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	27042 Towne Centre Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 270
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Lake Forest
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92610
CY2023	dei	City Area Code CityAreaCode	949
CY2023	dei	Local Phone Number LocalPhoneNumber	361-1200
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	7185686
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	BIOL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32522593
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	324
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	Macias Gini & O’Connell, LLP
CY2023	dei	Auditor Location AuditorLocation	Irvine, CA
CY2022	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2022	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6566000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4181000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	244000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2164000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5483000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5841000
CY2023Q4	us-gaap	Inventory Net InventoryNet	11433000
CY2022Q4	us-gaap	Inventory Net InventoryNet	15884000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1381000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3053000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	24863000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	28959000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5525000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4278000
CY2023Q4	us-gaap	Goodwill Goodwill	2926000
CY2022Q4	us-gaap	Goodwill Goodwill	2926000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1519000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1768000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	268000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	255000
CY2023Q4	us-gaap	Assets Assets	35101000
CY2022Q4	us-gaap	Assets Assets	38186000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6065000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5786000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8881000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9210000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2452000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2111000
CY2023Q4	us-gaap	Mediumterm Notes Current MediumtermNotesCurrent	2265000
CY2022Q4	us-gaap	Mediumterm Notes Current MediumtermNotesCurrent	700000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21675000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19663000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17807000
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	256000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	418000
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	593000
CY2022Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	360000
CY2023Q4	us-gaap	Mediumterm Notes Noncurrent MediumtermNotesNoncurrent	11782000
CY2022Q4	us-gaap	Mediumterm Notes Noncurrent MediumtermNotesNoncurrent	13091000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	772000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1259000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	79000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	362000
CY2023Q4	us-gaap	Liabilities Liabilities	33145000
CY2022Q4	us-gaap	Liabilities Liabilities	33297000
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2203000
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3416000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3416000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	317103000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	301790000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-553000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-733000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316800000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-296168000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-247000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4889000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35101000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38186000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49164000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48462000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	32440000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	32551000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	22659000
CY2023	us-gaap	Gross Profit GrossProfit	16724000
CY2022	us-gaap	Gross Profit GrossProfit	15911000
CY2021	us-gaap	Gross Profit GrossProfit	16529000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18441000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15339000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10216000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12309000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11258000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6004000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7265000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6048000
CY2023	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	0
CY2022	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	0
CY2021	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	315000
CY2023	us-gaap	Operating Expenses OperatingExpenses	34661000
CY2022	us-gaap	Operating Expenses OperatingExpenses	41249000
CY2021	us-gaap	Operating Expenses OperatingExpenses	32960000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-17937000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25338000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16431000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-351000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-438000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-452000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2361000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2749000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2224000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3014000
CY2023	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	48000
CY2022	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2664000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3187000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	338000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20601000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28525000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16093000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	109000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20632000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28634000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	180000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20452000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28744000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16396000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20632000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28634000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2023	biol	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-16987000
CY2022	biol	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-217000
CY2021	biol	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-546000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37619000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28851000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16704000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-29.44
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-29.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-418.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-418.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-283.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-283.12
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1278000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1278000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	10028000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13291000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000
CY2021	biol	Issuance Of Common Stock For Settlement Of Liability IssuanceOfCommonStockForSettlementOfLiability	510000
CY2021	biol	Issuance Of Restricted Shares During Period Value IssuanceOfRestrictedSharesDuringPeriodValue	164000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2416000
CY2021	biol	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	15063000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16158000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25208000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5602000
CY2022	biol	Issuance Of Restricted Shares During Period Value IssuanceOfRestrictedSharesDuringPeriodValue	109000
CY2022	biol	Phant Award Reclass PhantAwardReclass	596000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2117000
CY2022	biol	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	1000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28634000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4889000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9553000
CY2023	biol	Stock Issued During Period Shares Preferred Stock Warrants Exercised StockIssuedDuringPeriodSharesPreferredStockWarrantsExercised	20000
CY2023	biol	Stockissuedduringperiodpreferredstockwarrantsexercisedvalue Stockissuedduringperiodpreferredstockwarrantsexercisedvalue	1385000
CY2023	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	-0
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1331000
CY2023	biol	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	114000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20632000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	180000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-247000
CY2023	us-gaap	Profit Loss ProfitLoss	-20632000
CY2022	us-gaap	Profit Loss ProfitLoss	-28634000
CY2021	us-gaap	Profit Loss ProfitLoss	-16158000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2798000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	497000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	533000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	40000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-202000
CY2023	biol	Inventory Excess And Obsolescence InventoryExcessAndObsolescence	715000
CY2022	biol	Inventory Excess And Obsolescence InventoryExcessAndObsolescence	1312000
CY2021	biol	Inventory Excess And Obsolescence InventoryExcessAndObsolescence	-275000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1486000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	-122000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	426000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1196000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	515000
CY2023	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	0
CY2022	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	0
CY2021	biol	Patent Litigation Mark To Market PatentLitigationMarkToMarket	315000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-494000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2023	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares	0
CY2022	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares	109000
CY2021	biol	Issuance Of Restricted Shares IssuanceOfRestrictedShares	164000
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	447000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1232000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2303000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1662000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3014000
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	141000
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-201000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1643000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	978000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-969000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5754000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1375000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1527000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1135000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-285000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1851000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3521000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1765000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	179000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-59000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	308000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14091000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26761000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16710000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1311000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3727000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	707000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30175000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1918000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	182000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1129000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3727000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-707000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9553000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5602000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14420000
CY2023	biol	Proceeds From The Sale Of Convertible Preferred Stock Net Of Fees ProceedsFromTheSaleOfConvertiblePreferredStockNetOfFees	5490000
CY2022	biol	Proceeds From The Sale Of Convertible Preferred Stock Net Of Fees ProceedsFromTheSaleOfConvertiblePreferredStockNetOfFees	0
CY2021	biol	Proceeds From The Sale Of Convertible Preferred Stock Net Of Fees ProceedsFromTheSaleOfConvertiblePreferredStockNetOfFees	0
CY2023	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants	1743000
CY2022	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants	0
CY2021	biol	Proceeds From Sale Of Common Stock Warrants ProceedsFromSaleOfCommonStockWarrants	0
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1135000
CY2023	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan	165000
CY2022	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan	1000000
CY2021	biol	Principal Payment On Term Loan PrincipalPaymentOnTermLoan	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	25000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	114000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16562000
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	699000
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	132000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17434000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4603000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29954000
CY2023	biol	Effect Of Exchange Rate Changes EffectOfExchangeRateChanges	171000
CY2022	biol	Effect Of Exchange Rate Changes EffectOfExchangeRateChanges	-109000
CY2021	biol	Effect Of Exchange Rate Changes EffectOfExchangeRateChanges	-238000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2385000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25994000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12299000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4181000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30175000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17876000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6566000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4181000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2452000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2111000
CY2023	biol	Contract With Customer Liability Revenue Recognized Undelivered Elements ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements	400000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1519000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1771000
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	9000
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	26000
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	56000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	41000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	59000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	171000
CY2023	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	302000
CY2022	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	254000
CY2021	biol	Cash Paid For Operating Leases CashPaidForOperatingLeases	246000
CY2023	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	0
CY2022	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	0
CY2021	biol	Non Cash Settlement Of Performance Award Liability NonCashSettlementOfPerformanceAwardLiability	510000
CY2023	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	483000
CY2022	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	574000
CY2021	biol	Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation	150000
CY2023	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	217000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	546000
CY2023	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets	0
CY2022	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets	0
CY2021	biol	Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets	-1498000
CY2023	biol	Non Cash Property Plant And Equipment Additions Acquired Under Inventory NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory	2768000
CY2022	biol	Non Cash Property Plant And Equipment Additions Acquired Under Inventory NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory	0
CY2021	biol	Non Cash Property Plant And Equipment Additions Acquired Under Inventory NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory	0
CY2023	biol	Common Stock Issued Upon Exercise Of Preferred Stock CommonStockIssuedUponExerciseOfPreferredStock	22037000
CY2022	biol	Common Stock Issued Upon Exercise Of Preferred Stock CommonStockIssuedUponExerciseOfPreferredStock	0
CY2021	biol	Common Stock Issued Upon Exercise Of Preferred Stock CommonStockIssuedUponExerciseOfPreferredStock	0
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-17900000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25300000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16400000
CY2023Q4	biol	Working Capital WorkingCapital	5200000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6600000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5500000
CY2022Q4	biol	Working Capital WorkingCapital	11200000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4200000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5800000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14100000
CY2023	biol	Capital Expenditures CapitalExpenditures	1300000
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16800000
CY2022	biol	Contract With Customer Liability Revenue Recognized Undelivered Elements ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements	800000
CY2023	biol	Contract With Customer Liability Revenue Recognized Extended Warranty ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty	1300000
CY2023	us-gaap	Depreciation Depreciation	2800000
CY2022	us-gaap	Depreciation Depreciation	500000
CY2021	us-gaap	Depreciation Depreciation	400000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	447000
CY2023Q4	biol	Contract With Customer Liability In Extended Warranty Contracts ContractWithCustomerLiabilityInExtendedWarrantyContracts	2259000
CY2022Q4	biol	Contract With Customer Liability In Extended Warranty Contracts ContractWithCustomerLiabilityInExtendedWarrantyContracts	2082000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2708000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2529000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	256000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	418000
CY2023	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.89
CY2022	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.88
CY2021	biol	Revenue From Products And Services Transferred To Customers Percentage RevenueFromProductsAndServicesTransferredToCustomersPercentage	0.88
CY2023	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.11
CY2022	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.12
CY2021	biol	Revenue From Services Transferred To Customers Over Time Percentage RevenueFromServicesTransferredToCustomersOverTimePercentage	0.12
CY2022Q4	biol	Contract With Customer Liability Deferred Revenue Undelivered Elements ContractWithCustomerLiabilityDeferredRevenueUndeliveredElements	400000
CY2023Q4	biol	Contract With Customer Liability Deferred Revenue Undelivered Elements ContractWithCustomerLiabilityDeferredRevenueUndeliveredElements	400000
CY2023Q4	biol	Contract With Customer Liability In Undelivered Elements ContractWithCustomerLiabilityInUndeliveredElements	449000
CY2022	biol	Contract With Customer Liability Revenue Recognized Extended Warranty ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty	1400000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49164000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48462000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49164000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48462000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49164000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48462000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1653000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1086000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1132000
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	3733000
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	3639000
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1747000
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3472000
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3072000
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1793000
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1914000
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1653000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1086000
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	593000
CY2022Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	360000
CY2021Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	521000
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1321000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1293000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	565000
CY2023	us-gaap	Advertising Expense AdvertisingExpense	800000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1500000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1400000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1200000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2300000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1232000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2303000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1662000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	400000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1000000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.11
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35800000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31200000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4061000000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27000000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9000000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2200000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6168000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6697000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1299000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1871000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3966000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7316000
CY2023Q4	us-gaap	Inventory Net InventoryNet	11433000
CY2022Q4	us-gaap	Inventory Net InventoryNet	15884000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2500000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2200000
CY2023	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	700000
CY2022	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	2800000
CY2021	biol	Write Downs For Excess And Obsolete Inventory Expense WriteDownsForExcessAndObsoleteInventoryExpense	300000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	588000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	662000
CY2023Q4	biol	Prepaid Inventory PrepaidInventory	238000
CY2022Q4	biol	Prepaid Inventory PrepaidInventory	1225000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	555000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1166000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1381000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3053000
CY2023Q4	biol	Property Plant And Equipment Gross Excluding Land PropertyPlantAndEquipmentGrossExcludingLand	16695000
CY2022Q4	biol	Property Plant And Equipment Gross Excluding Land PropertyPlantAndEquipmentGrossExcludingLand	12661000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11330000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8538000
CY2023Q4	biol	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	5365000
CY2022Q4	biol	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	4123000
CY2023Q4	us-gaap	Land Land	160000
CY2022Q4	us-gaap	Land Land	155000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5525000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4278000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	biol	Cumulative Adjustment Depreciation Expense CumulativeAdjustmentDepreciationExpense	800000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3343000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4674000
CY2023Q4	biol	Preferred Stock Warrant Liability PreferredStockWarrantLiability	1363000
CY2022Q4	biol	Preferred Stock Warrant Liability PreferredStockWarrantLiability	0
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1321000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1293000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	888000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	638000
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	473000
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	490000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	452000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	432000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	422000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	591000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	619000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1092000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8881000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9210000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q4	biol	Discount Rate For Fair Value Level3 DiscountRateForFairValueLevel3	0.191
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023Q4	us-gaap	Goodwill Goodwill	2900000
CY2022Q4	us-gaap	Goodwill Goodwill	2900000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2800000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2800000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2800000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2800000
CY2023	biol	Indefinite Lived Intangible Assets Useful Life IndefiniteLivedIntangibleAssetsUsefulLife	indefinite life
CY2022	biol	Indefinite Lived Intangible Assets Useful Life IndefiniteLivedIntangibleAssetsUsefulLife	indefinite life
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	2926000
CY2023Q4	us-gaap	Goodwill Goodwill	2926000
CY2022Q4	us-gaap	Goodwill Goodwill	2926000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	40000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	15000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	70000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	47000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	110000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	64000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1000
CY2023	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	-1000
CY2022	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	-1000
CY2021	biol	Deferred Income Tax Expense Benefit Adjustment DeferredIncomeTaxExpenseBenefitAdjustment	1000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	109000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.219
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.928
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.342
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.006
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.042
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.045
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0
CY2023	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards	0
CY2022	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards	0
CY2021	biol	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards	-0
CY2023	biol	Effectiveincometaxratereconciliationnetoperatingloss382 Writeoffs Effectiveincometaxratereconciliationnetoperatingloss382Writeoffs	0
CY2022	biol	Effectiveincometaxratereconciliationnetoperatingloss382 Writeoffs Effectiveincometaxratereconciliationnetoperatingloss382Writeoffs	1.134
CY2021	biol	Effectiveincometaxratereconciliationnetoperatingloss382 Writeoffs Effectiveincometaxratereconciliationnetoperatingloss382Writeoffs	0
CY2023	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	0.001
CY2022	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	-0.012
CY2021	biol	Effectiveincometaxratereconciliationeffectofprioryeartrue Ups EffectiveincometaxratereconciliationeffectofprioryeartrueUps	-0.043
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.011
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-38000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-38000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	1353000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	2409000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	65000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	106000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1382000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1500000
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	5000
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	6000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1498000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1496000
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1179000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1024000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	591000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	186000
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	10000
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	113000
CY2023Q4	biol	Deferred Tax Assets Disallowed Interest DeferredTaxAssetsDisallowedInterest	2726000
CY2022Q4	biol	Deferred Tax Assets Disallowed Interest DeferredTaxAssetsDisallowedInterest	2167000
CY2023Q4	biol	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	416000
CY2022Q4	biol	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	475000
CY2023Q4	biol	Deferredtaxassetscapitalizedresearchorexperimentalexpenses Deferredtaxassetscapitalizedresearchorexperimentalexpenses	1601000
CY2022Q4	biol	Deferredtaxassetscapitalizedresearchorexperimentalexpenses Deferredtaxassetscapitalizedresearchorexperimentalexpenses	1456000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27476000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21665000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37062000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	32565000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35806000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31235000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1256000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1330000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	668000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	664000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	380000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	442000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	167000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	190000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1215000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1296000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	41000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	34000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35800000
CY2023	biol	Operating Loss Carryforwards Expirations Period OperatingLossCarryforwardsExpirationsPeriod	2038
CY2022	biol	Research And Development Federal Tax Credit Carryforwards Expiration Date Year ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear	2022
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	509000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	159000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	350000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Four LongTermDebtMaturitiesRepaymentsOfInterestInYearFour	6000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	147000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year After Four LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour	83000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	14710000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest LongTermDebtMaturitiesRepaymentsOfInterest	2882000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2022	biol	Unrecognizedtaxbenefitsreductionsresultingfromreductionduetosection382 Limitation Unrecognizedtaxbenefitsreductionsresultingfromreductionduetosection382Limitation	-131000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	219000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	219000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
CY2023	biol	Current Inome Related To Global Intangible Low Taxed Income CurrentInomeRelatedToGlobalIntangibleLowTaxedIncome	0
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	14047000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	13791000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2265000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	700000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11782000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13091000
CY2018	biol	Loan Exit Fees Percentage LoanExitFeesPercentage	0.08
CY2019Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	200000
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	100000
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.143
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2265000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths	1867000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12295000
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Two LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo	917000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0
CY2023Q4	biol	Long Term Debt Maturities Repayments Of Interest In Year Three LongTermDebtMaturitiesRepaymentsOfInterestInYearThree	9000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3000
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-12-31
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2020Q1	biol	Lease Facility Area LeaseFacilityArea	11000
CY2020Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-07-01
CY2021Q4	biol	Lease Facility Area LeaseFacilityArea	15000
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-06-30
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P66M
CY2020Q1	biol	Lease Facility Area LeaseFacilityArea	12000
CY2020Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-07-01
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	302000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	254000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	483000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	574000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.123
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.123
CY2023	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Description LesseeOperatingLeaseLeaseNotYetCommencedDescription	the only lease that had not commenced was for the additional training facility and model dental office lease in Foothill Ranch, California
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1049000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	817000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1869000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	209000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1660000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	888000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	638000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	772000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1259000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1660000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1897000
CY2023	us-gaap	Payments For Rent PaymentsForRent	1200000
CY2022	us-gaap	Payments For Rent PaymentsForRent	1000000
CY2021	us-gaap	Payments For Rent PaymentsForRent	900000
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	12600000
CY2021Q1	biol	Litigation Settlement Shares Issued LitigationSettlementSharesIssued	200
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	600000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1000000
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2575
CY2021Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	14400000
CY2023	us-gaap	Dividends Dividends	0
CY2022	us-gaap	Dividends Dividends	0
CY2021	us-gaap	Dividends Dividends	0
CY2020Q2	biol	Other Offering Expenses OtherOfferingExpenses	700000
	biol	Warrants Adjusted Exercise Price WarrantsAdjustedExercisePrice	1500
CY2018Q1	biol	Warrants Exercisable WarrantsExercisable	2500000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	908
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7400
CY2021	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	0
CY2021	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	2000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	950
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17925
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6201
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15000
CY2022	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	0
CY2022	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2282
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7254.45
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2023	biol	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue	0
CY2023	biol	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11718.01
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6293.55
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6293.55
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2023	biol	Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod	0
CY2023	biol	Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1000000
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	0
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6293.55
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	0
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6293.55
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	132000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	82000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.66
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	42000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	404000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	300000
CY2023Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	35000000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5525000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4278000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1067000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49164000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48462000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39188000
CY2023	us-gaap	Error Corrections And Prior Period Adjustments Description ErrorCorrectionsAndPriorPeriodAdjustmentsDescription	In connection with the preparation of the Company’s financial statements as of December 31, 2023, management identified an error related to the calculation of net loss per share attributable to common stockholders. As discussed in Note 8, the Company presents Series H Convertible Preferred Stock and Series J convertible Preferred Stock as mezzanine equity on balance sheet as these are contingently redeemable stock. Further, as discussed in Note 8, Series H and Series J Convertible Preferred Stock have been accreted to their redemption value in the period of their issuance following the SEC staff guidance on redeemable preferred stock.Per accounting guidance, the increases or decreases in the carrying amount of a redeemable preferred stock instrument should be treated in the same manner as dividends on nonredeemable stock. Therefore, increases or decreases in the carrying amount of preferred instruments subject to the SEC staff guidance above reduce or increase the EPS numerator. This adjustment to net loss attributable to common stockholders was not presented in previously furnished interim financial statements for periods ended June 30, 2023, and September 30, 2023. Management determined the impact of this error to be immaterial to the previously issued June 30, 2023, and September 30, 2023 interim financial statements.
CY2023Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	500000

Files In Submission

Name	View Source	Status
0000950170-24-034812-index-headers.html	Edgar Link	pending
0000950170-24-034812-index.html	Edgar Link	pending
0000950170-24-034812.txt	Edgar Link	pending
0000950170-24-034812-xbrl.zip	Edgar Link	pending
biol-20231231.htm	Edgar Link	pending
biol-20231231.xsd	Edgar Link	pending
biol-ex10_20.htm	Edgar Link	pending
biol-ex10_21.htm	Edgar Link	pending
biol-ex10_27.htm	Edgar Link	pending
biol-ex21_1.htm	Edgar Link	pending
biol-ex23_1.htm	Edgar Link	pending
biol-ex23_2.htm	Edgar Link	pending
biol-ex31_1.htm	Edgar Link	pending
biol-ex31_2.htm	Edgar Link	pending
biol-20231231_htm.xml	Edgar Link	completed
biol-ex32_1.htm	Edgar Link	pending
biol-ex32_2.htm	Edgar Link	pending
biol-ex4_1.htm	Edgar Link	pending
biol-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIOLQ
BIOLASE, INC Stock $biolq

2024 Q1 Form 10-K Financial Statement

#000095017024034812 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ BIOLASE, INC Stock $biolq

2024 Q1 Form 10-K Financial Statement

#000095017024034812 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOLQ
BIOLASE, INC Stock $biolq